0001193125-22-278560.txt : 20221107 0001193125-22-278560.hdr.sgml : 20221107 20221107081503 ACCESSION NUMBER: 0001193125-22-278560 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221107 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221107 DATE AS OF CHANGE: 20221107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oyster Point Pharma, Inc. CENTRAL INDEX KEY: 0001720725 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 811030955 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39112 FILM NUMBER: 221363821 BUSINESS ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 106 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: (609) 382-9032 MAIL ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 106 CITY: PRINCETON STATE: NJ ZIP: 08540 8-K 1 d409438d8k.htm 8-K 8-K
false 0001720725 0001720725 2022-11-07 2022-11-07

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 7, 2022

 

 

Oyster Point Pharma, Inc.

(Exact name of Registrant as Specified in Charter)

 

 

 

Delaware   001-39112   81-1030955

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

202 Carnegie Center, Suite 106  
Princeton, New Jersey   08540
(Address of Principal Executive Offices)   (Zip Code)

 

202 Carnegie Center, Suite 109  
Princeton, New Jersey   08540
(Former address of principal executive offices)   (Zip Code)

(609) 382-9032

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   OYST   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

Item 8.01 Other Events.

On November 7, 2022, Oyster Point, Inc., a Delaware corporation (“Oyster Point”) issued a press release announcing the execution of a Merger Agreement (the “Merger Agreement”), made and entered into as of November 7, 2022 by and among Oyster Point, Viatris Inc., a Delaware corporation and Iris Purchaser Inc., a Delaware corporation and a wholly owned subsidiary of Viatris Inc. (“Purchaser”). A copy of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

Additional Information about the Transaction and Where to Find It

The tender offer for the outstanding common stock of Oyster Point Pharma Inc. (“OP”) has not yet been commenced. This Current Report on Form 8-K does not constitute a recommendation, an offer to purchase or a solicitation of an offer to sell OP securities. At the time the tender offer is commenced, Viatris Inc. (“Parent”) and Iris Purchaser Inc., a direct wholly owned subsidiary of Parent (“Purchaser”), will file a Tender Offer Statement on Schedule TO (including an Offer to Purchase) with the Securities and Exchange Commission (the “SEC”) and thereafter, OP will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC, in each case, with respect to the Tender Offer. The solicitation and the offer by Parent to purchase shares of OP’s common stock will only be made pursuant to such Offer to Purchase and related materials. Once filed, investors and security holders are urged to read these materials (including the Offer to Purchase, a related Letter of Transmittal and certain other tender offer documents, as each may be amended or supplemented from time to time) carefully since they will contain important information that OP investors and security holders should consider before making any decision regarding tendering their common stock, including the terms and conditions of the tender offer. The Tender Offer Statement, Offer to Purchase, Solicitation/Recommendation Statement and related materials will be filed with the SEC, and OP investors and security holders may obtain a free copy of these materials (when available) and other documents filed by Parent, Purchaser and OP with the SEC at the website maintained by the SEC at www.sec.gov. In addition, the Tender Offer Statement and other documents that Parent and Purchaser file with the SEC will be made available to all investors and security holders of OP free of charge from the information agent for the tender offer. Investors may also obtain, at no charge, the documents filed with or furnished to the SEC by OP under the “Investors & Media” section of OP’s website at https://oysterpointrx.com.

Forward-Looking Statements

To the extent that statements contained in this Current Report on Form 8-K are not statements of historical facts, they may be deemed to be forward-looking statements. In some cases, such forward-looking statements can be identified by terms such as “believes,” “plans,” “anticipates,” “continue,” “potential,” “seek,” “goal,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Such forward-looking statements are based on management’s current expectations, beliefs, estimates, projections and assumptions. As such, forward-looking statements are not guarantees of future performance and involve inherent risks and uncertainties that are difficult to predict. As a result, a number of important factors could cause actual results to differ materially from those indicated by such forward-looking statements, including: the risk that the proposed acquisition of Oyster Point Pharma Inc. (“OP”) by Viatris Inc. (“Parent”) may not be completed; the possibility that competing offers or acquisition proposals for OP will be made; the delay or failure of the tender offer conditions to be satisfied (or waived), including insufficient shares of OP common stock being tendered in the tender offer; the failure (or delay) to receive the required regulatory approvals of the proposed acquisition; the possibility that prior to the completion of the transactions contemplated by the acquisition agreement, Parent’s or OP’s business may experience significant disruptions due to transaction-related uncertainty; the effects of disruption from the transactions of OP’s business and the fact that the announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, manufacturers, suppliers, vendors, business partners and distribution channels to patients; the occurrence of any event, change or other circumstance that could give rise to the termination of the acquisition agreement; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the failure of the closing conditions set forth in the acquisition agreement to be satisfied (or waived); the possibility that OP’s expectations as to the extent to which OP will be able to continue to commercialize TYRVAYA® (varenicline solution) Nasal Spray and any of OP’s other products and product candidates may not be realized as anticipated; the possibility that the anticipated scope, rate of progress and cost of OP’s preclinical studies and clinical trials and other research and development that OP may not materialize; the possibility that OP’s estimates of its expenses, ongoing losses, future revenue, capital requirements and its needs for

or ability to obtain additional financing may not be accurate; the possibility that OP’s expectations may not be met as to the sufficiency of its capital resources; the possibility that OP’s expectations may not be met as to its ability to obtain and maintain intellectual property protection for its products and any of its product candidates; the possibility that OP’s anticipated receipt and timing of royalties from its collaborators may not be realized as anticipated; the possibility that OP’s expectations may not be met as to the revenues from its collaborations; the possibility that OP’s expectations may not be met as to OP’s ability to retain and recruit key personnel and third-party distributors; the possibility that OP’s expectations may not be met as to its anticipated financial performance; the possibility that OP’s expectations may not be met as to its anticipated developments and projections relating to its competitors or the industry in which OP operates; the possibility that unforeseen safety issues could emerge for TYRVAYA Nasal Spray that could require OP to change the prescribing information, limit use of the product and/or result in litigation; the possibility that other manufacturers could obtain approval for generic versions of TYRVAYA Nasal Spray or of products with which OP competes; the possibility that the third-party organizations that manufacture, supply and distribute TYRVAYA Nasal Spray may fail to perform adequately or fulfill OP’s needs; the possibility that changes in healthcare law and implementing regulations may occur and may negatively impact OP’s ability to generate revenues or could limit or prevent OP’s products’ or product candidates’ commercial success; the possibility that regulatory filings for products or product candidates that OP or its partners develop are not made or granted as currently anticipated; the possibility that OP is not able to negotiate adequate pricing, coverage and adequate reimbursement for its products and product candidates with third parties and government authorities; the possibility of political, social and economic instability, natural disasters or public health epidemics in countries where OP or its collaborators conduct activities related to OP’s business; and a variety of other risks set forth from time to time in Parent’s or OP’s filings with the SEC, including but not limited to the risks discussed in Parent’s Annual Report on Form 10-K for the year ended December 31, 2021 and in other filings with the SEC and the risks discussed in OP’s Annual Report on Form 10-K for the year ended December 31, 2021 and in its other filings with the SEC. The risks and uncertainties may be amplified by the COVID-10 pandemic, which has caused significant economic uncertainty. The extent to which the COVID-19 pandemic impacts Parent’s and OP’s businesses, operations and financial results, including the duration and magnitude of such effects, will depend on numerous factors, which are unpredictable, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. The reader is cautioned not to unduly rely on these forward-looking statements. Parent and OP expressly disclaim any intent or obligation to update or revise publicly these forward-looking statements except as required by law.

Item 9.01 Financial Statements and Exhibits.

 

(d)

Exhibits

 

Exhibit No.   

Description

99.1    Press Release, dated November 7, 2022
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    OYSTER POINT PHARMA, INC.
Dated: November 7, 2022    
    By:  

/s/ Jeffrey Nau

      Jeffrey Nau, Ph.D., M.M.S.
      President, Chief Executive Officer and Director
 EX-99.1 2 d409438dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris

 

  •  

Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per Share

PRINCETON, N.J., November 7, 2022 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”), today announced that it has entered into a definitive agreement under which Viatris Inc. (Nasdaq: VTRS), a global healthcare company, would acquire Oyster Point Pharma, a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. Viatris intends to acquire Oyster Point Pharma as the foundation of its new ophthalmology franchise, recognizing its uniquely talented team, the strength of TYRVAYA® (varenicline solution) Nasal Spray and Oyster Point Pharma’s pipeline.

Under the terms of the agreement, Viatris will commence a tender offer to purchase all outstanding shares of Oyster Point Pharma for $11.00 per share in cash at closing, plus a contingent value right (“CVR”) for a potential cash payment of up to $2.00 per share upon achievement of specified performance targets by Oyster Point Pharma for full year 2022.

The transaction was unanimously approved by the Oyster Point Pharma Board of Directors.

“Oyster Point Pharma brings to Viatris the strength of TYRVAYA Nasal Spray, the first and only FDA-approved nasal spray for dry eye in the U.S., an eye care focused pipeline, and a very experienced team that possesses extensive knowledge of the ophthalmology space from a clinical, medical, regulatory and commercial perspective,” said Michael Goettler, chief executive officer of Viatris. “Together, we believe we are setting the foundation for the next global ophthalmology leader, accelerating efforts to address the unmet needs of patients with ophthalmic disease and the eye care professionals who treat them, and positioning Viatris for growth.”

“We are pleased to announce Viatris’ proposed acquisition of Oyster Point Pharma, recognizing the exciting opportunities that lie ahead of us,” said Jeffrey Nau, Ph.D., MMS, president and chief executive officer of Oyster Point Pharma. “Through our efforts to license our innovations globally, we recognized that Viatris would be an optimal partner with its Global Healthcare Gateway. With Viatris’ global capabilities and commitment to ophthalmology, we expect to be able to expand TYRVAYA’s impact on the dry eye landscape and accelerate our exciting pipeline. With our combined sector expertise, innovation, scale, pipeline and global commercial reach, we expect to build a world-class ophthalmology business to meaningfully shape the future of eye care, to the benefit of patients.”

In November 2021, Oyster Point Pharma launched TYRVAYA, the first and only FDA-approved nasal spray for the treatment of the signs and symptoms of dry eye disease. In addition, Oyster Point Pharma has a growing pipeline of clinical and pre-clinical programs aimed at delivering transformative innovation for ocular surface diseases. In addition to TYRVAYA, Oyster Point Pharma has three drug candidates in its pipeline: two investigational therapies for neurotrophic keratopathy, a severe degenerative condition affecting the nerves of the cornea, and another for vernal/atopic keratoconjunctivitis, a severe allergic condition of the eyes.

 

1

Transaction Terms and Financing

Under the terms of the agreement, Viatris will initiate a tender offer to acquire all of the outstanding shares of Oyster Point Pharma’s common stock at a price of $11.00 per share in cash at closing, plus a contingent value right (“CVR”) representing the right to receive a potential cash payment of up to $2.00 per share. The amount (if any) payable under the CVR will be based on the following performance targets to be achieved by Oyster Point Pharma for full year 2022:

 

  •  

An additional $1.00 per share in cash if Oyster Point Pharma generates equal to or greater than $21.6 million of net product revenues and 131,822 total prescriptions of TYRVAYA; or

 

  •  

An additional $2.00 per share in cash if Oyster Point Pharma generates equal to or greater than $24.0 million of net revenue and 146,469 total prescriptions of TYRVAYA.

The transaction is subject to customary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and the tender of a majority of the outstanding shares of Oyster Point Pharma’s common stock. Oyster Point Pharma stockholders holding approximately 46% of Oyster Point Pharma’s common stock have entered into a tender and support agreement with Viatris, pursuant to which such stockholders have agreed, among other things, to tender 100% of their shares of Oyster Point Pharma’s common stock in the tender offer, subject to the terms and conditions of such agreement.

Following the successful closing of the tender offer, Viatris will acquire all remaining shares of Oyster Point Pharma’s common stock that are not tendered into the tender offer through a second-step merger at the same price of $11.00 per share, plus a CVR representing the right to receive up to $2.00 per share.

The transaction is anticipated to close during the first quarter of 2023.

Earnings Conference Call

Given the proposed transaction, Oyster Point Pharma will not be hosting the previously scheduled earnings conference call on Thursday, November 10, 2022.

Advisors

Centerview Partners LLC is serving as the exclusive financial advisor to Oyster Point Pharma, and Cooley LLP is serving as legal counsel. Citigroup Global Markets Inc. is serving as the exclusive financial advisor to Viatris, and Cravath, Swaine & Moore LLP is serving as legal counsel.

About Oyster Point Pharma

Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. In October 2021, Oyster Point Pharma received FDA-approval for TYRVAYA (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease. Oyster Point Pharma has a growing pipeline of clinical and pre-clinical programs and continues to expand its research and development pipeline through internal innovation and external collaborations. Oyster Point Pharma is continuously striving to advance breakthrough science and deliver therapies seeking to address the unmet needs of patients with ophthalmic disease and the eye care professionals who take care of them. For more information, visit www.oysterpointrx.com and follow @OysterPointRx Twitter and LinkedIn.

 

2

About TYRVAYA® (varenicline solution) Nasal Spray

TYRVAYA (varenicline solution) Nasal Spray 0.03 mg is a highly selective cholinergic agonist that is FDA-approved to treat the signs and symptoms of dry eye disease as a multidose nasal spray. The parasympathetic nervous system, the “rest and digest” system of the body, controls tear film homeostasis partially via the trigeminal nerve, which is accessible within the nose. The efficacy of TYRVAYA Nasal Spray in dry eye disease is believed to be the result of varenicline’s activity at heteromeric sub-type(s) of the nicotinic acetylcholine (nACh) receptor where its binding produces agonist activity and activates the trigeminal parasympathetic pathway resulting in increased production of basal tear film as a treatment for dry eye disease. Varenicline binds with high affinity and selectivity at human α4ß2, α4α6ß2, α3ß4, α3α5ß4 and α7 neuronal nicotinic acetylcholine receptors. The exact mechanism of action is unknown at this time.

TYRVAYA® Important Safety Information

The most common adverse reaction reported in 82% of patients was sneezing. Events that were reported in 5-16% of patients were cough, throat irritation, and instillation-site (nose) irritation. There are no contraindications associated with TYRVAYA (varenicline solution) Nasal Spray. Please see full Prescribing Information at www.tyrvaya-pro.com/prescribinginformation.

About Dry Eye Disease and the Role of Tear Film

Dry eye disease is a chronic condition that impacts an estimated 38 million people in the U.S. and is growing in prevalence.1,2 It can cause persistent stinging, scratching, burning sensations, sensitivity to light, blurred vision, and eye fatigue. Dry eye disease is a multifactorial disease of the ocular surface characterized by disruption of the tear film. Human tear film is a complex mixture of more than 1,500 different proteins, including growth factors and antibodies, as well as numerous classes of lipids and mucins.3 Natural tear film protects and lubricates the eyes, washes away foreign particles, contains growth factors and antimicrobial components, and creates a smooth surface that forms the primary refractive surface of the eye.

Additional Information About the Tender Offer and Where to Find It

The tender offer for the outstanding common stock of Oyster Point Pharma Inc. (“OP”) has not yet been commenced. This press release does not constitute a recommendation, an offer to purchase or a solicitation of an offer to sell OP securities. At the time the tender offer is commenced, Viatris Inc. (“Parent”) and Iris Purchaser Inc., a direct wholly owned subsidiary of Parent, will file a Tender Offer Statement on Schedule TO (including an Offer to Purchase) with the Securities and Exchange Commission (the “SEC”) and thereafter, OP will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC, in each case, with respect to the Tender Offer. The solicitation and the offer by Parent to purchase shares of OP’s common stock will only be made pursuant to such Offer to Purchase and related materials. Once filed, investors and security holders are urged to read these materials (including the Offer to Purchase, a related Letter of Transmittal and certain other tender offer documents, as each may be amended or supplemented from time to time) carefully since they will contain important information that OP investors and security holders should consider before making any decision regarding tendering their common stock, including the terms and conditions of the tender offer. The Tender Offer Statement, Offer to Purchase, Solicitation/Recommendation Statement and related materials will be filed with the SEC, and OP investors and security holders may obtain a free copy of these materials (when available) and other documents filed by Parent, Purchaser and OP with the SEC at the website maintained by the SEC at www.sec.gov. In addition, the Tender Offer Statement and other documents that Parent and Purchaser file with the SEC will be made available to all investors and security holders of OP free of charge from the information agent for the tender offer. Investors may also obtain, at no charge, the documents filed with or furnished to the SEC by OP under the “Investors & Media” section of OP’s website at https://oysterpointrx.com.

 

3

Forward-Looking Statements

To the extent that statements contained in this press release] are not statements of historical facts, they may be deemed to be forward-looking statements. In some cases, such forward-looking statements can be identified by terms such as “believes,” “plans,” “anticipates,” “continue,” “potential,” “seek,” “goal,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Such forward-looking statements are based on management’s current expectations, beliefs, estimates, projections and assumptions. As such, forward-looking statements are not guarantees of future performance and involve inherent risks and uncertainties that are difficult to predict. As a result, a number of important factors could cause actual results to differ materially from those indicated by such forward-looking statements, including: the risk that the proposed acquisition of Oyster Point Pharma Inc. (“OP”) by Viatris Inc. (“Parent”) may not be completed; the possibility that competing offers or acquisition proposals for OP will be made; the delay or failure of the tender offer conditions to be satisfied (or waived), including insufficient shares of OP common stock being tendered in the tender offer; the failure (or delay) to receive the required regulatory approvals of the proposed acquisition; the possibility that prior to the completion of the transactions contemplated by the acquisition agreement, Parent’s or OP’s business may experience significant disruptions due to transaction-related uncertainty; the effects of disruption from the transactions of OP’s business and the fact that the announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, manufacturers, suppliers, vendors, business partners and distribution channels to patients; the occurrence of any event, change or other circumstance that could give rise to the termination of the acquisition agreement; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the failure of the closing conditions set forth in the acquisition agreement to be satisfied (or waived); the possibility that OP’s expectations as to the extent to which OP will be able to continue to commercialize TYRVAYA® (varenicline solution) Nasal Spray and any of OP’s other products and product candidates may not be realized as anticipated; the possibility that the anticipated scope, rate of progress and cost of OP’s preclinical studies and clinical trials and other research and development that OP may not materialize; the possibility that OP’s estimates of its expenses, ongoing losses, future revenue, capital requirements and its needs for or ability to obtain additional financing may not be accurate; the possibility that OP’s expectations may not be met as to the sufficiency of its capital resources; the possibility that OP’s expectations may not be met as to its ability to obtain and maintain intellectual property protection for its products and any of its product candidates; the possibility that OP’s anticipated receipt and timing of royalties from its collaborators may not be realized as anticipated; the possibility that OP’s expectations may not be met as to the revenues from its collaborations; the possibility that OP’s expectations may not be met as to OP’s ability to retain and recruit key personnel and third-party distributors; the possibility that OP’s expectations may not be met as to its anticipated financial performance; the possibility that OP’s expectations may not be met as to its anticipated developments and projections relating to its competitors or the industry in which OP operates; the possibility that unforeseen safety issues could emerge for TYRVAYA Nasal Spray that could require OP to change the prescribing information, limit use of the product and/or result in litigation; the possibility that other manufacturers could obtain approval for generic versions of TYRVAYA Nasal Spray or of products with which OP competes; the possibility that the third-party organizations that manufacture, supply and distribute TYRVAYA Nasal Spray may fail to perform adequately or fulfill OP’s needs; the possibility that changes in healthcare law and implementing regulations may occur and may negatively impact OP’s ability to generate revenues or could limit or prevent OP’s products’ or product candidates’ commercial success; the possibility that regulatory filings for products or product candidates that OP or its partners develop are not made or granted as currently anticipated; the possibility that OP is not able to negotiate adequate pricing, coverage and adequate reimbursement for its products and product candidates with third parties and government authorities; the

 

4

possibility of political, social and economic instability, natural disasters or public health epidemics in countries where OP or its collaborators conduct activities related to OP’s business; and a variety of other risks set forth from time to time in Parent’s or OP’s filings with the SEC, including but not limited to the risks discussed in Parent’s Annual Report on Form 10-K for the year ended December 31, 2021 and in other filings with the SEC and the risks discussed in OP’s Annual Report on Form 10-K for the year ended December 31, 2021 and in its other filings with the SEC. The risks and uncertainties may be amplified by the COVID-10 pandemic, which has caused significant economic uncertainty. The extent to which the COVID-19 pandemic impacts Parent’s and OP’s businesses, operations and financial results, including the duration and magnitude of such effects, will depend on numerous factors, which are unpredictable, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. The reader is cautioned not to unduly rely on these forward-looking statements. Parent and OP expressly disclaim any intent or obligation to update or revise publicly these forward-looking statements except as required by law.

References:

 

  1.

Wirta, D., Vollmer, P., Paauw, J., Chiu, K. H., Henry, E., Striffler, K., ... & ONSET-2 Study Group. (2021). Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease: the ONSET-2 Phase 3, Randomized Trial. Ophthalmology. https://doi.org/10.1016/j.ophtha.2021.11.004

 

  2.

Market-Scope. 2020 Dry Eye Products Report: A Global Market Analysis for 2019 to 2025. October 2020.

 

  3.

Tsubota K, Pflugfelder S, Liu Z, Baudouin C. Defining dry eye from a clinical perspective. Int J Mol Sci. 2020;21(23):1-24. https://pubmed.ncbi.nlm.nih.gov/33291796/

For more information, contact:

INVESTORS:

Arty Ahmed, +1.646.436.4702, aahmed@oysterpointrx.com

MEDIA:

Karen Castillo-Paff, +1.347.920.0248, kpaff@oysterpointrx.com

 

5

EX-101.SCH 3 oyst-20221107.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 oyst-20221107_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key EX-101.PRE 5 oyst-20221107_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g409438g1106213710775.jpg GRAPHIC begin 644 g409438g1106213710775.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Nov. 07, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 07, 2022
Entity Registrant Name Oyster Point Pharma, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39112
Entity Tax Identification Number 81-1030955
Entity Address, Address Line One 202 Carnegie Center, Suite 106
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08540
City Area Code 609
Local Phone Number 382-9032
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol OYST
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
Amendment Flag false
Entity Central Index Key 0001720725
XML 8 d409438d8k_htm.xml IDEA: XBRL DOCUMENT 0001720725 2022-11-07 2022-11-07 false 0001720725 8-K 2022-11-07 Oyster Point Pharma, Inc. DE 001-39112 81-1030955 202 Carnegie Center, Suite 106 Princeton NJ 08540 08540 609 382-9032 false false false false Common Stock, par value $0.001 per share OYST NASDAQ true true EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d409438d8k.htm d409438dex991.htm oyst-20221107.xsd oyst-20221107_lab.xml oyst-20221107_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d409438d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d409438d8k.htm" ] }, "labelLink": { "local": [ "oyst-20221107_lab.xml" ] }, "presentationLink": { "local": [ "oyst-20221107_pre.xml" ] }, "schema": { "local": [ "oyst-20221107.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "oyst", "nsuri": "http://oysterpointrx.com/20221107", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d409438d8k.htm", "contextRef": "duration_2022-11-07_to_2022-11-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d409438d8k.htm", "contextRef": "duration_2022-11-07_to_2022-11-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://oysterpointrx.com//20221107/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001193125-22-278560-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-278560-xbrl.zip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end